TrialFrontiers in immunology2024

Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.

Josep M Llibre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.